Foundation for the National Institutes of Health

What Foundation for the National Institutes of Health does

The Foundation for the National Institutes of Health (FNIH) is a Congressionally chartered 501(c)(3) nonprofit founded in 1990 and headquartered in North Bethesda, Maryland. It functions as the official convening partner of the National Institutes of Health, creating and managing public-private partnerships that connect NIH investigators with biopharmaceutical companies, academic researchers, philanthropic foundations, and patient advocacy groups. Over its 35-year history, FNIH has raised more than $1.56 billion from individual donors, corporate partners, and major foundations (including the Bill and Melinda Gates Foundation, Doris Duke Charitable Foundation, and McKnight Brain Research Foundation) to support more than 600 research programs across 30+ countries, directing more than 85 cents of every dollar spent to direct program support.\n\nFNIH does not develop proprietary technology products. Its core "technology" is the orchestration infrastructure for collaborative biomedical research — a portfolio of major partnership programs including the Accelerating Medicines Partnership (AMP) across Alzheimer's, ALS, autoimmune diseases, heart failure, Parkinson's, schizophrenia, and metabolic disorders; the Biomarkers Consortium (which has produced 40+ FDA-qualified biomarkers/endpoints and supported 20+ drug approvals); PACT ($220M Cancer Moonshot partnership with 12 pharma companies); Lung-MAP (a master-protocol lung cancer trial with 3,050 patients enrolled); ACTIV (COVID-19 therapeutics, stood up March 2020); RECOVER-TLC (Long COVID); A-PLUS (maternal health); and GeneConvene Global Collaborative (genetic biocontrol). The AMP Knowledge Portals aggregate structured datasets from 160,000+ patients and serve 2,500+ researchers worldwide. AI/ML surfaces in selected programs, notably a predictive model for Alzheimer's symptom onset using plasma p-tau217 protein levels, but FNIH's role is data stewardship rather than model development.\n\nFNIH's revenue model is charitable fundraising across three streams: individual donations, corporate contributions (primarily membership dues and program-specific sponsorship from life sciences companies), and foundation grants. It operates no commercial pricing or product sales; its economic engine is convening authority and the ability to deploy donor capital into pre-competitive biomedical research that no single sector would fund alone. The organization is governed by a board drawn from life sciences, venture capital, and academia, and is led by President and CEO Julie Louise Gerberding (former CDC Director, appointed May 2022). Revenue figures are not publicly disclosed, but the scale of program commitments implies gross inflows well into the eight figures annually, with the vast majority passed through to research partners and academic institutions.

Name

Foundation for the National Institutes of Health

Legal name

Foundation for the National Institutes of Health

Website

https://fnih.org

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

101–250 employees

Short description

The Foundation for the National Institutes of Health is a Congressionally chartered 501(c)(3) nonprofit that creates and manages public-private partnerships connecting NIH researchers with biopharma, academia, and patient advocacy groups to accelerate biomedical breakthroughs across 30+ countries.

Ownership category

akta.pro rank

Product category

Biomedical Research Partnership Management

NAICS

Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Health and Welfare Funds (52512)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Research & Science Grantmaking Foundations (BPAGAKAI), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Biomedical research partnerships
• Public-private partnerships
• Clinical trial coordination
• Biomarker qualification
• Nonprofit health foundation

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Individual Donations: FNIH receives charitable contributions from individuals who support biomedical research initiatives. The foundation has devoted more than $1.56 billion to support research programs since inception.
2. Corporate Contributions: Life science companies contribute funding to participate in public-private partnerships coordinated by FNIH. Membership dues from the private sector fund core activities such as the Biomarkers Consortium.
3. Foundation Grants: Philanthropic organizations including the Bill and Melinda Gates Foundation, Doris Duke Charitable Foundation, and others provide grants and fellowships to support specific research initiatives and training programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

The Foundation for the National Institutes of Health (FNIH) is a not-for-profit 501(c)(3) charitable organization chartered by Congress in 1990 that creates and leads public-private partnerships supporting NIH's mission. It convenes NIH researchers with biopharma, academia, and patient advocacy groups to advance biomedical discovery, biomarker qualification, and clinical trials across multiple disease areas. The foundation manages research portfolio programs and raises private funds from individuals, corporations, and philanthropic organizations to support these initiatives.

Product overview

The Foundation for the National Institutes of Health (FNIH) operates as a not-for-profit 501(c)(3) charitable organization that creates and leads public-private partnerships to advance biomedical research. Rather than offering a single unified product, FNIH manages a portfolio of research partnership programs including: Accelerating Medicines Partnership® (AMP®) for target validation across multiple disease areas, the Biomarkers Consortium for biomarker qualification, GeneConvene Global Collaborative for genetic biocontrol research, RECOVER-TLC for Long COVID therapeutics, ACTIV for COVID-19 interventions, A-PLUS for maternal health, Lung-MAP for lung cancer trials, and PACT for cancer immunotherapy biomarkers. These programs connect NIH researchers with biopharma, academia, and patient advocacy groups to accelerate medical breakthroughs.

Differentiator

Problem solved

Functional benefit

Brands

• Accelerating Medicines Partnership (AMP): A public-private partnership program managed by FNIH to improve understanding of disease pathways and accelerate new therapies to patients.
• Biomarkers Consortium
• GeneConvene Global Collaborative
• RECOVER-TLC
• ACTIV (Accelerating COVID-19 Therapeutic Interventions & Vaccines)

Products and services

• Accelerating Medicines Partnership (AMP) A pre-competitive public-private partnership program that improves understanding of disease pathways, facilitates better selection of targets for treatment, and identifies platforms and processes to accelerate new and effective therapies to patients. Includes disease-specific initiatives covering Alzheimer's, ALS, autoimmune diseases, metabolic diseases, heart failure, Parkinson's, and schizophrenia.
• Biomarkers Consortium
• GeneConvene Global Collaborative
• RECOVER-TLC (Researching COVID to Enhance Recovery–Treating Long COVID)
• ACTIV (Accelerating COVID-19 Therapeutic Interventions & Vaccines) A public-private partnership assembled to coordinate research and clinical testing efforts against COVID-19, establishing a national research agenda for prioritizing and speeding development of COVID-19 vaccines and therapeutics.
• A-PLUS (Azithromycin Prevention in Labor Use Study)
• Lung-MAP (Master Protocol for Treatment of Non-Small Cell Lung Cancer)
• PACT (Partnership for Accelerating Cancer Therapies)
• Edmond J. Safra Family Lodge
• Education & Training Programs

Quantifiable outcome

• More than $1.56 billion raised to support research programs
• +7 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

26 partnerships are on record, tiered core and minor.

• Alexandria Real Estate Equities, Inc./Alexandria Venture InvestmentscoreStrategic or Co-development Partner · 22 October 2025Awarded 2025 Charles A. Sanders, MD, Partnership Award for leadership in MAP-D public-private partnership developing precision medicine framework for depression. First phase launching May 2026.
• FDAcoreStrategic or Co-development Partner · 1 August 2025FDA leads collaborative effort with FNIH and international agencies to develop New Approach Methodologies (NAMs) as alternatives to animal testing in preclinical research.
• European CommissioncoreStrategic or Co-development Partner · 1 August 2025International regulatory partner in the Validation and Qualification Network (VQN) to advance alternative methods to animal testing.
• SanoficoreStrategic or Co-development Partner · 1 August 2025Pharmaceutical partner in VQN public-private initiative to help NAMs gain regulatory acceptance for use in drug development.
• Novo NordiskcoreStrategic or Co-development Partner · 1 August 2025Pharmaceutical partner in VQN initiative for animal testing alternatives in drug development.
• GSKcoreStrategic or Co-development Partner · 1 August 2025Pharmaceutical partner in VQN initiative for alternative testing methodologies.
• Charles River LaboratoriescoreStrategic or Co-development Partner · 1 August 2025Contract research organization partner in VQN for standardizing and validating NAMs as replacements for animal testing.
• AstraZenecacoreStrategic or Co-development PartnerAstraZeneca collaborates with FNIH as part of obesity and weight management research partnerships, working on multi-pathway solutions targeting GLP-1, amylin, glucagon, and activin pathways.
• EccogeneminorStrategic or Co-development PartnerCollaboration focused on advancing next-generation therapies for obesity and type 2 diabetes.
• CSPC PharmaceuticalsminorStrategic or Co-development PartnerCollaboration partner in obesity and diabetes therapeutic development.
• SOPHIA ConsortiumminorStrategic or Co-development PartnerConsortium partner in obesity research and therapeutic development.
• Monument TherapeuticscoreStrategic or Co-development PartnerMonument Therapeutics collaborated with FNIH on the Accelerating Medicines Partnership Schizophrenia program for clinical trial of MT1988 in patients at clinical high risk for psychosis.
• AmgencoreStrategic or Co-development PartnerAmgen Scholars Program at NIH and Amgen Foundation support education and training programs.
• Boston UniversitycoreStrategic or Co-development PartnerAcademic partner in A-PLUS study for maternal health research.
• Columbia UniversitycoreStrategic or Co-development PartnerAcademic partner in A-PLUS maternal health study.
• University of North Carolina at Chapel HillcoreStrategic or Co-development PartnerAcademic partner in A-PLUS maternal health research.
• 70+ Companies and Nonprofits (Biomarkers Consortium)coreStrategic or Co-development PartnerBiomarkers Consortium includes over 70 companies and nonprofit organizations working on biomarker validation and qualification.
• AbbViecoreStrategic or Co-development PartnerLung-MAP partner company supporting targeted therapy development for non-small cell lung cancer.
• AmgencoreStrategic or Co-development PartnerLung-MAP partner company for lung cancer clinical trial master protocol.
• Bristol-Myers SquibbcoreStrategic or Co-development PartnerLung-MAP partner for cancer therapy development.
• Roche/GenentechcoreStrategic or Co-development PartnerLung-MAP partner supporting targeted cancer therapy research.
• PfizercoreStrategic or Co-development PartnerLung-MAP partner for cancer clinical trial coordination.
• National Cancer InstitutecoreStrategic or Co-development PartnerPublic sector partner supporting Lung-MAP clinical trial network.
• 12 Leading Pharmaceutical Companies (PACT)coreStrategic or Co-development PartnerPACT includes 12 leading pharmaceutical companies as part of Cancer Moonshot initiative, focused on biomarker identification for immune therapies.
• National Institutes of HealthcoreStrategic or Co-development PartnerNIH leads PACT initiative as part of Cancer Moonshot, with FNIH managing the partnership.
• NIH Alumni Network PartnersminorOthersFNIH partnered with FAES (Foundation for Advanced Education in the Sciences), Office of NIH History & Stetten Museum, and NIH Office of Communications and Public Liaison to provide resources to NIH alumni.

Scale indicators18 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Milken Institute: Milken Institute operates as a nonpartisan think tank convening public-private partnerships in health and medical research, including FasterCures and the Melanoma Research Alliance. It is comparable to FNIH in its role as a convener of cross-sector partnerships to accelerate biomedical progress.
• Research!America: Research!America is a nonprofit alliance advocating for increased investment in medical and health research. It is comparable to FNIH in its focus on the U.S. biomedical research ecosystem and convening stakeholders across industry, academia, and government.
• Doris Duke Charitable Foundation: Doris Duke Charitable Foundation is a direct peer in the medical research grantmaking space and an active FNIH funder supporting scientific fellowships and biomedical research initiatives. Both organizations are private foundations funding biomedical research with similar philanthropic missions.
• Critical Path Institute (C-Path): C-Path is a nonprofit that creates consortia among industry, FDA, and academia to qualify biomarkers, clinical outcome assessments, and drug development tools. It is a direct peer in the biomarker qualification and regulatory science space, often collaborating with FNIH's Biomarkers Consortium.
• National Health Council: The National Health Council brings together patient advocacy groups, providers, and researchers to advance chronic disease research. It is comparable to FNIH in its role as a convener of patient advocacy, industry, and research communities to accelerate treatment development.

Broad incumbents

• Howard Hughes Medical Institute: HHMI is a major biomedical research organization that funds and operates its own research labs and investigator programs. It is comparable to FNIH in its focus on advancing biomedical science through sustained philanthropic support, though HHMI runs a much larger investigator-based model rather than a partnership-convening model.
• Bill & Melinda Gates Foundation: The Gates Foundation is one of the largest philanthropic funders of global health and biomedical research and a direct funder of FNIH programs. It is a comparable grantmaking foundation in the health/medical research space, though vastly larger in scale and operating a broader global development mandate.
• Robert Wood Johnson Foundation: Robert Wood Johnson Foundation is one of the largest U.S. health-focused philanthropic foundations, funding health research, policy, and programs. It is comparable as a major private health grantmaking foundation, though with a broader public-health/policy orientation than FNIH's biomedical research focus.

Regional players

• Alzheimer's Drug Discovery Foundation: ADDF is a disease-specific foundation funding drug discovery for Alzheimer's. It is comparable in operating model as a disease-focused grantmaking foundation with strong industry and academic networks, though narrower in therapeutic scope than FNIH.
• Melanoma Research Alliance: Melanoma Research Alliance is a disease-specific foundation funding melanoma research through public-private partnerships. It is comparable to FNIH in convening industry and academic partners around a specific disease, though at a much smaller scale and narrower focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/fnih_org
• Facebookfacebook.com/fnihorg
• LinkedInlinkedin.com/company/foundation-for-the-national-institutes-of-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Foundation for the National Institutes of Health